Two companies, Celldex and Clovis, reported positive developments with their strategies to target the mutated Epidermal Growth Factor Receptor for patients with glioblastoma and lung cancer. Continue reading

Two companies, Celldex and Clovis, reported positive developments with their strategies to target the mutated Epidermal Growth Factor Receptor for patients with glioblastoma and lung cancer. Continue reading